Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2020-09-04 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于闫凯境豁免要约收购天士力医药集团股份有限公司股份的2020年半年度持续督导意见
Capital/Financing Update Classification · 95% confidence The document is a detailed financial advisor's continuous supervision opinion report related to a specific acquisition transaction involving Yan Kaijing and Tasly Pharmaceutical Group Co., Ltd. It references the 2020 semi-annual report and covers the period from January 1, 2020 to June 30, 2020. The content includes transaction details, governance and compliance status, fulfillment of commitments, and future plans related to the acquisition. It is not a simple announcement or a brief summary but a substantive report with detailed analysis and opinions. The document is not an annual report or interim report of the company itself but a continuous supervision opinion related to a takeover exemption and acquisition process. This type of document aligns best with the category of Capital/Financing Update (CAP), as it deals with acquisition-related financial advisory and compliance supervision during a capital transaction. The document length (4073 characters) is substantial enough to be a report rather than a mere announcement. Therefore, the classification is CAP with high confidence.
2020-09-04 Chinese
关于所属子公司天士力生物医药股份有限公司首次公开发行股票并在科创板上市申请获上海证券交易所受理的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (741 characters) regarding the acceptance by the Shanghai Stock Exchange of the application for the initial public offering (IPO) and listing of a subsidiary company on the STAR Market. It states that the application materials have been accepted and the review process will continue, with a caution about investment risks. There is no detailed financial data, no full report, and no mention of attached reports. The document is an official regulatory announcement about the status of a capital market application, not a full financial report or detailed presentation. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-09-03 Chinese
关于以集中竞价交易方式回购公司股票的进展公告
Transaction in Own Shares Classification · 95% confidence The document is a progress announcement regarding the company's stock repurchase plan. It references previous announcements and reports about the stock buyback but primarily provides an update that no shares have been repurchased as of the end of August 2020. The document is short (745 characters) and focuses on the progress of a share repurchase program, which fits the category of a Transaction in Own Shares (POS) filing rather than a full report or announcement of a new report publication.
2020-08-31 Chinese
关于公司2020年半年度主要经营数据的公告
Regulatory Filings Classification · 95% confidence The document is titled as an announcement of the company's 2020 half-year main operating data, with detailed financial figures for the first half of 2020 compared to the same period in 2019. It includes revenue, cost, and gross margin data by industry, treatment area, product, and region. The document explicitly states that the data is unaudited and is an announcement of operating data rather than a full interim financial report. The length is 3452 characters, which is relatively short and consistent with a data announcement rather than a comprehensive interim report. There is no indication of full financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement of operating data without full financial statements or audit information.
2020-08-25 Chinese
半年度募集资金存放与使用报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金存放与实际使用情况的专项报告" which translates to a "Special Report on the Deposit and Actual Use of Raised Funds." It details the amount of funds raised, their usage, management, and any changes in investment projects related to the raised funds. The document includes detailed tables on the use of raised funds for the period January to June 2020, and explanations about project changes and fund management. It is not a general annual or quarterly financial report but a specific report focused on the use of capital raised through equity issuance. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is 7790 characters, which is substantive and contains detailed financial data related to fundraising usage, not just an announcement or summary. Therefore, the appropriate classification is CAP with high confidence.
2020-08-25 Chinese
第七届董事会第18次会议决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at the 18th meeting of the 7th Board of Directors of the company. It mentions the approval of the 2020 semi-annual report and other related reports, but it does not contain the actual financial data or the full report itself. Instead, it refers to the full semi-annual report being available on the stock exchange website. The document is short (774 characters) and serves as a formal announcement of board decisions rather than the report itself. Therefore, it fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain substantive financial data or the full report.
2020-08-25 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.